Cited by 57Infective Endocarditis Diagnosis and ManagementInfectious Aortic and Vascular ConditionsVascular Anomalies and Treatments

Probiotics and infective endocarditis in patients with hereditary hemorrhagic telangiectasia: a clinical case and a review of the literature

Open access
Boumis, Evangelo, Capone, Alessandro, Galati, Vincenzo, Venditti, Carolina, Petrosillo, Nicola·2018·BMC Infectious Diseases

Abstract

BACKGROUND: In the last decades, probiotics have been widely used as food supplements because of their putative beneficial health effects. They are generally considered safe but rare reports of serious infections caused by bacteria included in the definition of probiotics raise concerns on their potential pathogenic role in patients with particular predisposing factors. Patients with hereditary hemorrhagic telangiectasia (HHT) are exposed to infections because of telangiectasias and arteriovenous malformations (AVMs). We describe what is, to our knowledge, the first case of infective endocarditis (IE) caused by Lactobacillus rhamnosus in a patient with HHT. A systematic review of the relevant medical literature is presented. CASE PRESENTATION: A patient with HHT and an aortic bioprosthesis was admitted because of prolonged fever not responding to antibiotics. The patient had a history of repeated serious infections with hospitalizations and prolonged use of antibiotics, and used to assume large amounts of different commercial products containing probiotics. Weeks before the onset of symptoms the patient had been treated with nasal packings and with surgical closure of a nasal bleeding site because of recurrent epistaxis. A diagnosis of IE of the aortic bioprosthesis was made. All blood coltures were positive for L. rhamnosus. The patients responded to a cycle of 6 weeks of amoxicillin/clavulanate plus gentamicin. A systematic review of IE linked to consumption of probiotics, and of infective endocarditis in patients with HHT was conducted. 10 cases of IE linked to probiotics consumption and 6 cases of IE in patients with HHT were found. CONCLUSIONS: Consumption of probiotics can pose a risk of serious infections in patients with particular predisposing factors. Patients with HHT can be considered at risk because of their predisposition to infections. Prophylaxis with antibiotics before nasal packings in patients with HHT can be considered.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12879-018-2956-5

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Adverse events from probiotic strains in vulnerable populations include life-threatening pneumonia, endocarditis, and sepsis.

    “AEs include life-threatening pneumonia,106 endocarditis,107–111 and sepsis.112–115”

    From Emerging issues in probiotic safety: 2023 perspectives (2023) · cites this paper as [111]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 39 · Cited by 57

Authors
Boumis, E., Capone, A., Galati, V., Venditti, C., & Petrosillo, N.
Affiliations
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
Corresponding author
Boumis, Evangelo
Venue
BMC Infectious Diseases
Published
2018-02-01
Volume
18
Issue
1
Pages
65-65
ISSN
1471-2334 (ISSN-L)
OpenAlex
W2789849801
Cited by
57
References
39
Citations by year
2026: 4 · 2025: 7 · 2024: 5 · 2023: 8 · 2022: 5 · 2021: 5 · 2020: 9 · 2019: 9 · 2018: 4 · 2017: 1
FWCI
5.26
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Infectious Diseases (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Epidemiology › Infective Endocarditis Diagnosis and Management
  • Health Sciences › Medicine › Surgery › Infectious Aortic and Vascular Conditions
  • Health Sciences › Medicine › Genetics › Vascular Anomalies and Treatments
Keywords
probiotics, infective endocarditis, hereditary hemorrhagic telangiectasia, Lactobacillus rhamnosus, aortic bioprosthesis, arteriovenous malformation, epistaxis, antibiotic prophylaxis, nasal packing
MeSH terms
Aged, Amoxicillin, Anti-Bacterial Agents, Bioprosthesis, Endocarditis, Bacterial, Epistaxis, Gentamicins, Humans, Male, Telangiectasia, Hereditary Hemorrhagic, Dietary Supplements, Clavulanic Acid, Probiotics, Lacticaseibacillus rhamnosus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review